Yendou, a Berlin, Germany-based provider of a clinical operations automation platform, raised $1.3m in pre-seed funding.

Yendou是一家位于德国柏林的临床操作自动化平台提供商，在种子期前筹集了130万美元资金。

The round was led by us at b2venture, with support from Heartfelt, Infinite Fund, and several angel investors from the pharmaceutical industry, including Meri Beckwith, co-founder of the new CRO challenger Lindus Health.

这一轮由我们在b2venture领导，得到了衷心的无限基金和制药行业的几位天使投资者的支持，其中包括新CRO挑战者林德斯健康公司的联合创始人梅里·贝克维思。

The company intends to use the funds to expand operations and its development efforts.

该公司打算利用这些资金扩大业务和发展努力。

Led by CEO and co-founder Zina Sarif, and co-founder Patrick Rogg, Yendou provides a clinical operations automation platform to accelerate the operational efficiency of clinical trials. Since its launch in March 2023, the company has rapidly gathered attention and adoption from over 1,200 clinicians in 46 countries.

Yendou由首席执行官兼联合创始人Zina Sarif和联合创始人Patrick Rogg领导，提供临床操作自动化平台，以加速临床试验的操作效率。自2023年3月成立以来，该公司迅速受到46个国家1200多名临床医生的关注和采纳。

Following this success, Yendou opened its platform to pharmaceutical companies in a closed beta offering. This offering enables pharmaceutical and biotech companies to connect, select, and onboard clinical trial sites for Phase II and Phase III oncology trials seamlessly..

在取得这一成功后，Yendou以封闭测试的方式向制药公司开放了其平台。该产品使制药和生物技术公司能够无缝连接、选择和部署II期和III期肿瘤试验的临床试验站点。